EUVIMED · CrossrefZeitschrift
Leukemia
ISSN 0887-6924 · Springer Science and Business Media LLC
Neueste Artikel
Differentiation hierarchy in adult B-cell acute lymphoblastic leukemia at clonal resolution
Genomic and transcriptomic features associated with responses and outcomes of third-generation tyrosine kinase-inhibitor therapy in chronic myeloid leukemia
Survival trends in Waldenström macroglobulinemia and comparison of outcomes with the general United States population
In memoriam: Robert A. Kyle, M.D. (1928–2026)
Mediator kinase inhibition exposes a transcriptional vulnerability and synergizes with venetoclax in AML
Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells
Maternal donor risk in haploidentical transplant with post-transplant cyclophosphamide: the role of recipient sex
Hyperactivation of type I IFN signaling underlies a broad inflammatory program in VEXAS syndrome
Mutant calreticulin-driven myeloproliferative neoplasms favour the emergence of TIGIT-positive NK cells
Salvage therapy for immune-mediated bone marrow failure
Relcobatinib, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia
The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma
Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach
Mutant TP53 allelic states in human hematopoietic stem and progenitor cells
Clinical and molecular characteristics of FLT3-ITD microclones in elderly patients with acute myeloid leukemia receiving less-intensive therapy
Rapid proteasomal degradation of mutant feline McDonough sarcoma-like tyrosine kinase-3 overcomes inhibitor resistance mechanisms of acute myeloid leukemia cells
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry
PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation
Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms
Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms
Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial
Plasticity under pressure: biology and detection of lineage switch in acute leukemia
Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study
Unraveling cellular and molecular mechanisms of relapse in CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors
Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma
Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study
Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies
Jahrgänge
2026 · 3242025 · 3602024 · 3562023 · 3232022 · 3582021 · 4322020 · 4032019 · 3182018 · 3402017 · 4142016 · 3782015 · 3362014 · 3852013 · 4042012 · 3772011 · 2832010 · 3352009 · 3682008 · 4132007 · 4762006 · 4402005 · 4552004 · 3632003 · 4152002 · 4012001 · 3732000 · 3591999 · 7141998 · 3271997 · 354
EUVIMED